{"id":51339,"date":"2022-11-29T14:05:34","date_gmt":"2022-11-29T13:05:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/"},"modified":"2022-11-29T14:05:34","modified_gmt":"2022-11-29T13:05:34","slug":"bighat-biosciences-announces-research-collaboration-with-merck","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/","title":{"rendered":"BigHat Biosciences Announces Research Collaboration with Merck"},"content":{"rendered":"
\n

\nCollaboration leverages BigHat\u2019s AI-enabled platform to expedite protein engineering to design and develop novel therapeutic candidates<\/i>\n<\/p>\n

SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company\u2019s technology to design candidates for up to three drug discovery programs.\n<\/p>\n

<\/a><\/p>\n

\nBigHat\u2019s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins.\n<\/p>\n

\nUnder the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat\u2019s platform to synthesize, express, purify, and characterize molecules. Mark DePristo, co-founder and CEO of BigHat, continued, “We are thrilled to be collaborating with Merck’s world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.\u201d\n<\/p>\n

\nThe teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies. \u201cWe are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,\u201d said Elizabeth Schwarzbach, BigHat\u2019s Chief Business Officer. “This agreement with Merck brings us a major step closer to our goal of 3-5 deep collaborations with leading biopharmas to complement our internal therapeutic pipeline.”\n<\/p>\n

\n\u201cThis agreement with BigHat expands Merck\u2019s strategy of applying AI\/ML across our drug discovery capabilities,\u201d said Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories. \u201cWe look forward to working with the team to leverage BigHat\u2019s technology and expertise in enabling molecular design of novel biologic candidates.\u201d\n<\/p>\n

\nAbout BigHat Biosciences, Inc.
\n
<\/b>BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today\u2019s most challenging diseases. BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. BigHat\u2019s broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised over $100M from top investors, including Section 32, a16z, and 8VC. For more information, visit https:\/\/www.bighatbio.com\/<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBigHat: Elizabeth Schwarzbach, partnering@bighatbio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Collaboration leverages BigHat\u2019s AI-enabled platform to expedite protein engineering to design and develop novel therapeutic candidates SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company\u2019s technology … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51339","6":"format-standard","7":"category-industry"},"yoast_head":"\nBigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaboration leverages BigHat\u2019s AI-enabled platform to expedite protein engineering to design and develop novel therapeutic candidates SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company\u2019s technology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-29T13:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BigHat Biosciences Announces Research Collaboration with Merck\",\"datePublished\":\"2022-11-29T13:05:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/\"},\"wordCount\":436,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221129005191\\\/en\\\/1648521\\\/21\\\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/\",\"name\":\"BigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221129005191\\\/en\\\/1648521\\\/21\\\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg\",\"datePublished\":\"2022-11-29T13:05:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221129005191\\\/en\\\/1648521\\\/21\\\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221129005191\\\/en\\\/1648521\\\/21\\\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bighat-biosciences-announces-research-collaboration-with-merck\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BigHat Biosciences Announces Research Collaboration with Merck\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/","og_locale":"en_US","og_type":"article","og_title":"BigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend","og_description":"Collaboration leverages BigHat\u2019s AI-enabled platform to expedite protein engineering to design and develop novel therapeutic candidates SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company\u2019s technology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-29T13:05:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BigHat Biosciences Announces Research Collaboration with Merck","datePublished":"2022-11-29T13:05:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/"},"wordCount":436,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/","url":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/","name":"BigHat Biosciences Announces Research Collaboration with Merck - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg","datePublished":"2022-11-29T13:05:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221129005191\/en\/1648521\/21\/Flat-Color-Vertical-Logo-Horizontal_%285%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bighat-biosciences-announces-research-collaboration-with-merck\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BigHat Biosciences Announces Research Collaboration with Merck"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51339"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51339\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}